We’re excited to launch Paradigm’s new Investor Hub, your central access point for all the latest news, ASX announcements, and updates on our journey.

Paradigm is at a pivotal stage with our global Phase 3 trial of Zilosul® for knee osteoarthritis now underway. Over the next 12 months, key milestones, including 25%, 50%, 75% and full trial recruitment, plus the interim analysis, will shape the future of our Company.

This Hub is where you can follow our progress, access key developments as they happen, and stay connected with Paradigm as we advance towards delivering a much-needed treatment option for osteoarthritis patients worldwide.